PART1 and liver cancer: As shown in Figure 1(a), expression levels of PART1 and FOXC2 were significantly upregulated in the serum of liver cancer patients but that of miR-3529-3p significantly decreased (P < 0.05 or P < 0.01) compared with that of the normal group.